GI INNOVATION

Pipeline timeline for Research and Development on new drugs based on GI-SMART™ platform

Project	Indication	Discovery Pre-clinical Phase 1 Phase 2 Phase 3
Project : GI-101	Indication : Immuno-Oncology	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery GLP-Tox P1/2
Project : GI-101	(2019.11 out-licencing)
Project : GI-102	Indication : Immuno-Oncology	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery GLP-Tox P1/2
Project : GI-102
Project : GI-301	Indication : Allergic Diseases	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery GLP-Tox P1b
Project : GI-301	(2020.07 out-licencing) (2023.10 out-licencing)
Project : GI-108	Indication : Metabolic Immuno-oncology	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery GLP-Tox 1/2a
Project : GI-108
Project : GI-213	Indication : Obesity	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery
Project : GI-128	Indication : Immuno-Oncology	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery
Project : GI-10N	Indication : Immuno-Oncology	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery
Project : GI-30N	Indication : Allergic, Fibrotic Diseases	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery
Project : GI-20N	Indication : Metabolic Diseases	Discovery Pre-clinical Phase 1 Phase 2 Phase 3 상업화 Discovery

Research presentation	Title	Related Information
AACR2021	연구 발표 제목이 들어갑니다.	R&D capabilities press release
AACR2022	연구 발표 제목이 들어갑니다.	R&D capabilities press release
AACR2021	연구 발표 제목이 들어갑니다.	R&D capabilities press release
AACR2022	연구 발표 제목이 들어갑니다.	R&D capabilities press release
AACR2021	연구 발표 제목이 들어갑니다.	R&D capabilities press release
AACR2022	연구 발표 제목이 들어갑니다.	R&D capabilities press release